nach oben

Erschienen in:

03.12.2015 | Zertifizierte Fortbildung

Affektive Störungen

Akutbehandlung manischer Episoden

verfasst von: Dr. med. Michael Berger, Dr. med. Ute Lewitzka, Dr. med. Florian Seemüller

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die aktuellen Empfehlungen zur Akuttherapie manischer Episoden erfordern für eine Diagnose bestimmte Kernsymptome. Nach dem DSM-5 erhöht die Erweiterung des Manie-Kernkriteriums „gehobener Affekt“ durch die zusätzliche Forderung nach einem verstärkten Antrieb die diagnostische Spezifität. Die Auswahl einer passenden pharmakologischen Therapie sollte mit Rücksicht auf klinische Subtypen erfolgen.

Saß, H., H.-U. Wittchen, and M. Zaudig, Diagnostisches und statistisches Manual psychischer Störungen DSM-IV. Göttingen, Bern, Toronto, Seattle: Hogrefe. 1996.

Association, A.P., Diagnostic and Statistical Manual of Mental Disorders, 4th edition. Washington DC: American Psychiatric Association. 1994.

WHO, Internationale Klassifikation psychischer Störungen: ICD 10, Kapitel V, Klinisch-diagnostische Leitlinien, 4.durchgesehene und ergänzte Auflage ed. Bern, Göttingen, Toronto: Hans Huber. 2000.

Association, A.P., Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry, 2002. 159(4 Suppl): p. 1–50.

Berk, M., L. Berk, and D. Castle, A collaborative approach to the treatment alliance in bipolar disorder. Bipolar Disord, 2004. 6(6): p. 504–18.PubMedCrossRef

Yatham, L.N., et al., Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord, 2006. 8(6): p. 721–39.PubMedCrossRef

National Institute for Health and Clinical Excellence: NICE clinical guideline 38:Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. In, London: National Institute for Health and Clinical Excellence. 2006.

DGBS and DGPPN, S3-Leitlinie: Diagnostik und Therapie bipolarer Störungen, ed. DGBS and DGPPN. 2013: Springer. 474.

Hammond, W.A., A Treatise on Diseases of the Nervous System. New York: Appleton, 1871.

10.

Cade, J.F., Lithium salts in the treatment of psychotic excitement. Med J Aust, 1949. 2(10): p. 349–52.PubMed

11.

Schou, M., et al., The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry, 1954. 17(4): p. 250–60.PubMedCentralPubMedCrossRef

12.

Bowden, C.L., et al., Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA, 1994. 271(12): p. 918–24.PubMedCrossRef

13.

Bowden, C.L., et al., A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry, 2005. 66(1): p. 111–21.PubMedCrossRef

14.

Kushner, S.F., et al., Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord, 2006. 8(1): p. 15–27.PubMedCrossRef

15.

Keck, P.E., Jr., et al., Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry, 2007. 68(10): p. 1480–91.PubMedCrossRef

16.

Grunze, H., Lithium in the acute treatment of bipolar disorders-a stocktaking. Eur Arch Psychiatry Clin Neurosci, 2003. 253(3): p. 115–9.PubMedCrossRef

17.

Gouliaev, G., et al., Treatment of manic episodes: zuclopenthixol and clonazepam versus lithium and clonazepam. Acta Psychiatr Scand, 1996. 93(2): p. 119–24.PubMedCrossRef

18.

Berk, M., L. Ichim, and S. Brook, Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int Clin Psychopharmacol, 1999. 14(6): p. 339–43.PubMedCrossRef

19.

Niufan, G., et al., Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. J Affect Disord, 2008. 105(1-3): p. 101–8.PubMedCrossRef

20.

Segal, J., M. Berk, and S. Brook, Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol, 1998. 21(3): p. 176–80.PubMed

21.

Walton, S.A., M. Berk, and S. Brook, Superiority of lithium over verapamil in mania: a randomized, controlled, single-blind trial. J Clin Psychiatry, 1996. 57(11): p. 543–6.PubMedCrossRef

22.

Ichim, L., M. Berk, and S. Brook, Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatry, 2000. 12(1): p. 5–10.PubMedCrossRef

23.

Placidi, G.F., et al., The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients. J Clin Psychiatry, 1986. 47(10): p. 490–4.PubMed

24.

Lerer, B., et al., Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry, 1987. 48(3): p. 89–93.PubMed

25.

Lusznat, R.M., D.P. Murphy, and C.M. Nunn, Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry, 1988. 153: p. 198–204.PubMedCrossRef

26.

Okuma, T., et al., Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry, 1990. 23(3): p. 143–50.PubMedCrossRef

27.

Small, J.G., et al., Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry, 1991. 48(10): p. 915–21.PubMedCrossRef

28.

Freeman, T.W., et al., A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry, 1992. 149(1): p. 108–11.PubMedCrossRef

29.

Licht, R.W., Lithium in the treatment of acute mania, in Lithium in neuropsychiatry the comprehensive guide, M. Bauer, P. Grof, and B. Müller-Oerlinghausen, Editors. 2006, Informa Healthcare: London. p. 59–72.

30.

Swann, A.C., et al., Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology, 2002. 26(4): p. 530–6.PubMedCrossRef

31.

Burrow, G.N., et al., Effect of lithium on thyroid function. J Clin Endocrinol Metab, 1971. 32(5): p. 647–52.PubMedCrossRef

32.

Schiemann, U. and K. Hengst, Thyroid echogenicity in manic-depressive patients receiving lithium therapy. J Affect Disord, 2002. 70(1): p. 85–90.PubMedCrossRef

33.

Mak, T.W., et al., Effects of lithium therapy on bone mineral metabolism: a two-year prospective longitudinal study. J Clin Endocrinol Metab, 1998. 83(11): p. 3857–9.PubMed

34.

Berger, M., et al., Do current screening recommendations allow for early detection of lithium-induced hyperparathyroidism in patients with bipolar disorder? International Journal of Bipolar Disorders, 2013. 1(7).

35.

Yamaki, M., et al., Cellular mechanism of lithium-induced nephrogenic diabetes insipidus in rats. Am J Physiol, 1991. 261(3 Pt 2): p. F505–11.PubMed

36.

Tredget, J., A. Kirov, and G. Kirov, Effects of chronic lithium treatment on renal function. J Affect Disord, 2010. 126(3): p. 436–40.PubMedCrossRef

37.

Bendz, H., et al., Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int, 2010. 77(3): p. 219–24.PubMedCrossRef

38.

Swann, A.C., et al., Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry, 1997. 54(1): p. 37–42.PubMedCrossRef

39.

Emrich, H.M., et al., Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch Psychiatr Nervenkr (1970), 1980. 229(1): p. 1–16.PubMedCrossRef

40.

Pope, H.G., Jr., et al., Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry, 1991. 48(1): p. 62–8.PubMedCrossRef

41.

Bowden, C.L., et al., A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry, 2006. 67(10): p. 1501–10.PubMedCrossRef

42.

Muller-Oerlinghausen, B., et al., Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J Clin Psychopharmacol, 2000. 20(2): p. 195–203.PubMedCrossRef

43.

Macritchie, K., et al., Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev, 2003(1): p. CD004052.

44.

Bowden, C., et al., A 12-week, open, randomized trial comparing sodium valproate to lithium in patients with bipolar I disorder suffering from a manic episode. Int Clin Psychopharmacol, 2008. 23(5): p. 254–62.PubMedCrossRef

45.

McElroy, S.L., et al., A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry, 1996. 57(4): p. 142–6.PubMed

46.

Zajecka, J.M., et al., A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry, 2002. 63(12): p. 1148–55.PubMedCrossRef

47.

Kakkar, A.K., et al., Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study. Eur Psychiatry, 2009. 24(3): p. 178–82.PubMedCrossRef

48.

Vasudev, K., U. Goswami, and K. Kohli, Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology (Berl), 2000. 150(1): p. 15–23.CrossRef

49.

Keck, P.E., Jr., et al., Valproate oral loading in the treatment of acute mania. J Clin Psychiatry, 1993. 54(8): p. 305–8.PubMed

50.

Grunze, H., et al., Intravenous valproate loading in acutely manic and depressed bipolar I patients. J Clin Psychopharmacol, 1999. 19(4): p. 303–9.PubMedCrossRef

51.

Hirschfeld, R.M., et al., The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. J Clin Psychiatry, 2003. 64(7): p. 841–6.PubMedCrossRef

52.

Okuma, T., et al., Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis. A preliminary report. Folia Psychiatr Neurol Jpn, 1973. 27(4): p. 283–97.PubMed

53.

Ballenger, J.C. and R.M. Post, Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry, 1980. 137(7): p. 782–90.PubMedCrossRef

54.

Emrich, H.M., M. Dose, and D. von Zerssen, The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord, 1985. 8(3): p. 243–50.PubMedCrossRef

55.

Post, R.M., et al., Correlates of antimanic response to carbamazepine. Psychiatry Res, 1987. 21(1): p. 71–83.PubMedCrossRef

56.

Okuma, T., et al., Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology (Berl), 1979. 66(3): p. 211–7.CrossRef

57.

Klein, E., et al., Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Arch Gen Psychiatry, 1984. 41(2): p. 165–70.PubMedCrossRef

58.

Brown, D., T. Silverstone, and J. Cookson, Carbamazepine compared to haloperidol in acute mania. Int Clin Psychopharmacol, 1989. 4(3): p. 229–38.PubMedCrossRef

59.

Small, J.G., et al., Comparison of therapeutic modalities for mania. Psychopharmacol Bull, 1996. 32(4): p. 623–7.PubMed

60.

Weisler, R.H., et al., A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry, 2004. 65(4): p. 478–84.PubMedCrossRef

61.

Weisler, R.H., Extended-release carbamazepine capsules: a viewpoint. CNS Drugs, 2005. 19(8): p. 717–8.PubMedCrossRef

62.

Schneck, C.D., Bipolar Disorder in Neurologic Illness. Curr Treat Options Neurol, 2002. 4(6): p. 477–486.PubMedCrossRef

63.

Goncalves, N. and K.D. Stoll, [Carbamazepine in manic syndromes. A controlled double-blind study]. Nervenarzt, 1985. 56(1): p. 43–7.PubMed

64.

Elphick, M., An open clinical trial of carbamazepine in treatment-resistant bipolar and schizo-affective psychotics. Br J Psychiatry, 1985. 147: p. 198–200.PubMedCrossRef

65.

Keck, P.E., Jr., et al., A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry, 2003. 160(9): p. 1651–8.PubMedCrossRef

66.

Sachs, G., et al., Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol, 2006. 20(4): p. 536–46.PubMedCrossRef

67.

Young, A.H., et al., Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry, 2009. 194(1): p. 40–8.PubMedCrossRef

68.

McIntyre, R.S., et al., Aripiprazole: pharmacology and evidence in bipolar disorder. Expert Opin Pharmacother, 2007. 8(7): p. 1001–9.PubMedCrossRef

69.

Vieta, E., et al., Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry, 2008. 165(10): p. 1316–25.PubMedCrossRef

70.

Sanford, M. and L.J. Scott, Intramuscular aripiprazole: a review of its use in the management of agitation in schizophrenia and bipolar I disorder. CNS Drugs, 2008. 22(4): p. 335–52.PubMedCrossRef

71.

McIntyre, R.S., et al., Quetiapine or haloperidol as monotherapy for bipolar mania—a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol, 2005. 15(5): p. 573–85.PubMedCrossRef

72.

McElroy, S.L., et al., Placebo-controlled study of quetiapine monotherapy in ambulatory bipolar spectrum disorder with moderate-to-severe hypomania or mild mania. J Affect Disord, 2010. 124(1-2): p. 157–63.PubMedCrossRef

73.

Vieta, E., et al., A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord, 2010. 12(3): p. 230–43.PubMedCrossRef

74.

Li, H., et al., Response and remission rates in Chinese patients with bipolar mania treated for 4 weeks with either quetiapine or lithium: a randomized and double-blind study. Curr Med Res Opin, 2008. 24(1): p. 1–10.PubMedCrossRef

75.

Tohen, M., et al., Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry, 1999. 156(5): p. 702–9.PubMed

76.

Tohen, M., et al., Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry, 2000. 57(9): p. 841–9.PubMedCrossRef

77.

Tohen, M., et al., Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry, 2007. 164(10): p. 1547–56.PubMedCrossRef

78.

Tohen, M., et al., Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry, 2008. 69(11): p. 1776–89.PubMedCrossRef

79.

Tohen, M., et al., Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry, 2003. 160(7): p. 1263–71.PubMedCrossRef

80.

Perlis, R.H., et al., Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry, 2006. 67(11): p. 1747–53.PubMedCrossRef

81.

Hirschfeld, R.M., et al., Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry, 2004. 161(6): p. 1057–65.PubMedCrossRef

82.

Khanna, S., et al., Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry, 2005. 187: p. 229–34.PubMedCrossRef

83.

Smulevich, A.B., et al., Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol, 2005. 15(1): p. 75–84.PubMedCrossRef

84.

Scherk, H., F.G. Pajonk, and S. Leucht, Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry, 2007. 64(4): p. 442–55.PubMedCrossRef

85.

Keck, P.E., Jr., et al., Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry, 2003. 160(4): p. 741–8.PubMedCrossRef

86.

Potkin, S.G., et al., Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol, 2005. 25(4): p. 301–10.PubMedCrossRef

87.

Vieta, E., et al., Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. J Psychopharmacol, 2010. 24(4): p. 547–58.PubMedCrossRef

88.

Warrington, L., et al., Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder. CNS Drugs, 2007. 21(10): p. 835–49.PubMedCrossRef

89.

Greenberg, W.M. and L. Citrome, Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev, 2007. 13(2): p. 137–77.PubMedCrossRef

90.

McIntyre, R.S., Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder. Expert Rev Neurother, 2010. 10(5): p. 645–9.PubMedCrossRef

91.

McIntyre, R.S., et al., Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord, 2009. 11(8): p. 815–26.PubMedCrossRef

92.

Berwaerts, J., et al., Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study. J Affect Disord, 2012. 136(1-2): p. e51–60.PubMedCrossRef

93.

Sachs, G.S., et al., Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry, 2002. 159(7): p. 1146–54.PubMedCrossRef

94.

Cipriani, A., J.M. Rendell, and J.R. Geddes, Haloperidol alone or in combination for acute mania. Cochrane Database Syst Rev, 2006(3): p. CD004362.

95.

Thomas, P., E. Vieta, and S.s. group, Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open-label, randomized, comparative trial. Neuropsychiatr Dis Treat, 2008. 4(3): p. 675–86.PubMedCentralPubMedCrossRef

96.

Tohen, M., et al., Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry, 2008. 192(2): p. 135–43.PubMedCrossRef

97.

Tohen, M., et al., Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry, 2002. 59(1): p. 62–9.PubMedCrossRef

98.

Baker, R.W., et al., Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. Br J Psychiatry, 2004. 185: p. 472–8.PubMedCrossRef

99.

Sachs, G., et al., Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord, 2004. 6(3): p. 213–23.PubMedCrossRef

100.

Yatham, L.N., et al., A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania. Int Clin Psychopharmacol, 2007. 22(4): p. 212–20.PubMedCrossRef

101.

Yatham, L.N., et al., Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry, 2003. 182: p. 141–7.PubMedCrossRef

102.

Barekatain, M., et al., Valproate-risperidone valproate-lithium combination in acute mania. Journal of Research in Medical Sciences, 2005. 10(5): p. 274–280.

103.

Maina, G., et al., Valproate or olanzapine add-on to lithium: an 8-week, randomized, open-label study in Italian patients with a manic relapse. J Affect Disord, 2007. 99(1-3): p. 247–51.PubMedCrossRef

104.

Akhondzadeh, S., et al., Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord, 2006. 8(5 Pt 1): p. 485–9.PubMedCrossRef

105.

Machado-Vieira, R., et al., A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry, 2008. 69(8): p. 1237–45.PubMedCentralPubMedCrossRef

106.

Arnold, L.M., S.L. McElroy, and P.E. Keck, Jr., The role of gender in mixed mania. Compr Psychiatry, 2000. 41(2): p. 83–7.PubMedCrossRef

107.

Suppes, T., et al., Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network: a sex-specific phenomenon. Arch Gen Psychiatry, 2005. 62(10): p. 1089–96.PubMedCrossRef

108.

Himmelhoch, J.M. and M.E. Garfinkel, Sources of lithium resistance in mixed mania. Psychopharmacol Bull, 1986. 22(3): p. 613–20.PubMed

109.

Secunda, S.K., et al., Diagnosis and treatment of mixed mania. Am J Psychiatry, 1987. 144(1): p. 96–8.PubMedCrossRef

110.

Benabarre, A., et al., Treatment of mixed mania with risperidone and mood stabilizers. Can J Psychiatry, 2001. 46(9): p. 866–7.PubMed

111.

Vieta, E., The treatment of mixed states and the risk of switching to depression. Eur Psychiatry, 2005. 20(2): p. 96–100.PubMedCrossRef

112.

Vieta, E., et al., Role of risperidone in bipolar II: an open 6-month study. J Affect Disord, 2001. 67(1-3): p. 213–9.PubMedCrossRef

113.

Goodwin, F. and K. Jamison, Manic-depressive illness. Bipolar Disorders and Recurrent Depression. Vol. 2nd ed. 2007, {Oxford, New York: Oxford University Press}.

114.

Johnstone, E.C., et al., The Northwick Park „functional“ psychosis study: diagnosis and treatment response. Lancet, 1988. 2(8603): p. 119–25.PubMedCrossRef

115.

Kusumakar, V., et al., Treatment of mania, mixed state, and rapid cycling. Can J Psychiatry, 1997. 42 Suppl 2: p. 79S–86S.PubMed

116.

McElroy, S.L., P.E. Keck, Jr., and S.M. Strakowski, Mania, psychosis, and antipsychotics. J Clin Psychiatry, 1996. 57 Suppl 3: p. 14–26; discussion 47-9.PubMed

117.

Colom, F., et al., A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry, 2003. 60(4): p. 402–7.PubMedCrossRef

118.

Tohen, M., et al., The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord, 2009. 11(5): p. 453–73.PubMedCrossRef

119.

Hiremani, R.M., et al., Double-blind randomized controlled study comparing short-term efficacy of bifrontal and bitemporal electroconvulsive therapy in acute mania. Bipolar Disord, 2008. 10(6): p. 701–7.PubMedCrossRef

120.

Barekatain, M., et al., Bifrontal versus bitemporal electroconvulsive therapy in severe manic patients. J ECT, 2008. 24(3): p. 199–202.PubMedCrossRef

121.

Mohan, T.S., et al., Effects of stimulus intensity on the efficacy and safety of twice-weekly, bilateral electroconvulsive therapy (ECT) combined with antipsychotics in acute mania: a randomised controlled trial. Bipolar Disord, 2009. 11(2): p. 126–34.PubMedCrossRef

122.

Yildiz, A., et al., Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology, 2011. 36(2): p. 375–89.PubMedCentralPubMedCrossRef

Titel: Affektive Störungen
Akutbehandlung manischer Episoden
verfasst von: Dr. med. Michael Berger
Dr. med. Ute Lewitzka
Dr. med. Florian Seemüller
Publikationsdatum: 03.12.2015
Verlag: Springer Medizin
Erschienen in: DNP – Die Neurologie & Psychiatrie / Ausgabe 12/2015
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI: https://doi.org/10.1007/s15202-015-0845-y

Neu in den Fachgebieten Neurologie und Psychiatrie

23.04.2024 | Demenz | Nachrichten

Springer Medizin

Akutbehandlung manischer Episoden

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2015

MS-Therapie: Anhaltende Effekte auf Schubraten, EDSS-Score und Hirnatrophie

Orale MS-Therapie: Auch nach sieben Jahren kaum noch MS-Schübe

Schubtherapie bei Multipler Sklerose

Mit Fingolimod oder Natalizumab eskalieren?

Folsäure zur Primärprävention des Schlaganfalls möglicherweise sinnvoll

Sekundärprophylaxe nach Dissektion der Zervikalarterien

Neu in den Fachgebieten Neurologie und Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein